Cargando…

Effect of Wellness Education on Quality of Life of Patients With Non–Small Cell Lung Cancer Treated With First-Line Icotinib and on Their Family Caregivers

Objective: To examine the effects of a wellness-education intervention on quality of life (QOL) of patients with NSCLC treated with icotinib and on their caregivers. Methods: This feasibility study was a prospective pilot randomized controlled trial to evaluate a wellness-education intervention in N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yanwei, Ling, Li, Zhanyu, Pan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498762/ https://www.ncbi.nlm.nih.gov/pubmed/31043093 http://dx.doi.org/10.1177/1534735419842373

Ejemplares similares

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
por: Jiang, Zhansheng, et al.
Publicado: (2021)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
por: Xu, Jianping, et al.
Publicado: (2017)

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
por: Liang, Jun-Li, et al.
Publicado: (2014)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2016)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
por: LIN, Huawei, et al.
Publicado: (2020)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
por: Wang, Long, et al.
Publicado: (2021)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer
por: Liu, Zhicong, et al.
Publicado: (2022)

Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer
por: Li, Ke, et al.
Publicado: (2020)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
por: Zhang, Ying, et al.
Publicado: (2015)

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study
por: Chen, Xiaofeng, et al.
Publicado: (2014)

Caregiver Response to an Online Dementia and Caregiver Wellness Education Platform
por: Rodriguez, Katie, et al.
Publicado: (2021)

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone
por: Xu, Yunhua, et al.
Publicado: (2020)

A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer
por: Zhang, Bo
Publicado: (2023)

Traditional Chinese medicine formula 01 for nasopharyngeal carcinoma (NPC01) for head & neck cancer and health-related quality of life: a retrospective study
por: Yanwei, Li, et al.
Publicado: (2022)

Caregivers Like Me: An Education Intervention for Family Caregivers of Latino Elders at End-of-Life
por: Cruz-Oliver, Dulce M., et al.
Publicado: (2016)

Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines
por: Li, Ke, et al.
Publicado: (2019)

Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study
por: Zhang, Wen, et al.
Publicado: (2020)

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies
por: Biaoxue, Rong, et al.
Publicado: (2016)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
por: Liu, Tianze, et al.
Publicado: (2019)

Efficacy of icotinib in advanced lung squamous cell carcinoma
por: Liang, Shuai, et al.
Publicado: (2018)

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
por: Zhang, Chunxiang, et al.
Publicado: (2016)

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study
por: Hu, Xingsheng, et al.
Publicado: (2015)

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
por: Tan, Xueyun, et al.
Publicado: (2023)

Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report
por: Wu, Ka, et al.
Publicado: (2019)

Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis
por: Xiang, Min, et al.
Publicado: (2020)

Depression of Family Caregivers Is Associated with Disagreements on Life-Sustaining Preferences for Treating Patients with Dementia
por: Tsai, Chia-Fen, et al.
Publicado: (2015)

The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
por: Wang, Lulu, et al.
Publicado: (2018)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells
por: Yanwei, Li, et al.
Publicado: (2018)

The effect of supportive educative program on the quality of life in family caregivers of hemodialysis patients
por: Ghane, Golnar, et al.
Publicado: (2017)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Innovations in Workforce Education for Family Caregiving
por: Sexson, Kathryn, et al.
Publicado: (2021)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
por: Mao, Long-fei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aj2fuaa8dcraovtbf1kv65apgv